各项收入占比是对2025的估算，并非来自已提交报告的数字。
Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.
Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.
Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).
基于 Jazz Pharmaceuticals plc 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
US$241.38+0.4%11月13日 收盘
数据截至2026年9月30日，来自2026年11月2日提交的10-Q
Jazz sells low-sodium oxybate medicine for narcolepsy and idiopathic hypersomnia, plus epilepsy and cancer drugs to patients through pharmacies and hospitals.
公司指引：2026 财年营收 US$4.8B 至 US$4.9B — 同比增长 12.8%
Just reported
From Jazz Pharmaceuticals's results release of 2026年11月2日; its quarterly report has since been filed.
Actual
US$1.24B
+10% y/y
+2.9% q/q
Guided
—
No guide given
Actual
-US$7.48
Guided
—
No guide given
Actual
-US$413.4M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Jazz Pharmaceuticals plc 评级历史 41 个季度中的 2 个。 其余 39 个可回溯到 2016年11月。
